Skip to main content
Caplight Logo









Implican

Implican

Private
GroningenHealthcare & Life Scienceshttps://implican.nl/

Last Round

Seed

Jan 10, 2023

Total Funding Raised

$1.07M

Company Overview

Implican operates in Healthcare & Life Sciences and is based in Groningen. Its latest recorded funding round was a Seed round in January 2023.

Implican is a medical device company that develops anastomotic devices designed to reduce anastomotic leakage in colorectal surgery.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Implican Comparables

Compare Implican with similar companies based on industry and business-model similarity.

Implican comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CarpoNovum AB
87%
Seger Surgical Solutions
81%
Johnson & Johnson
76%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Implican Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 10, 2023
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Rik Kielman

Chief Executive Officer

Executive Team

For institutional investors. Book with your work email.

Implican Investors

Notable investors and investment history

Implican investors
InvestorRounds
Nextgen VenturesSeed
Noordelijke Ontwikkelings MaatschappijSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 21, 2026

    Monthly visitors increased 49% MoM.

  • Jan 1, 2026

    Monthly visitors increased 335% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

Implican Filings

Explore SEC and related filing metadata, where available.

Implican filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Implican's valuation, stock price, and market status.

Is Implican a public or private company?

Implican is a private company.

What is the current stock price of Implican?

Implican is a private company, so its shares have no public market price. Caplight tracks Implican's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Implican worth (valuation)?

Valuation information for Implican is not publicly available.

Can I buy Implican stock?

Implican shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Implican's last funding round?

Implican's most recent funding round was Seed on January 10, 2023.

Who are the main investors in Implican?

Key investors in Implican include Nextgen Ventures, Noordelijke Ontwikkelings Maatschappij.

Will Implican IPO soon?

No public IPO plans have been announced for Implican.

How can I track Implican secondary market activity?

Caplight tracks bids, offers, and trades in Implican's shares on secondary markets.

Firmographic Details

HeadquartersGroningen
Employee Range5
Year FoundedN/A
Last FundingJan 10, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?